XNCR - Xencor Inc

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.

52W High

$27.24

52W Low

$6.92

MA Status:

50D: Above 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.82

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-17.27

EV/Revenue (<3 favorable)

1.59

P/S (TTM) (<3 favorable)

4.15

P/B (<3 favorable)

0.98

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.23%

Institutions (25–75% balanced)

114.68%

Shares Outstanding

71,323,000

Float

64,446,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

146,929,000

Gross Profit (TTM)

-82,596,000

EPS (TTM)

-2.36

Profit Margin (>10% good)

-1.16%

Operating Margin (TTM) (higher better)

-0.76%

ROE (TTM) (>15% strong)

-0.29%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.82

Momentum

Bearish momentum

Value

0.1413

0.1204

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025